Frequency of Dyslipidemia in patients with Lupus Nephritis

Sajjad, Saba; Farman, Sumaira; Saeed, Muhammad Ahmed; Ahmad, Nighat; Butt, Bilal Azeem

doi:10.12669/pjms.332.12410

Cited by 11 publications

(11 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, studies have shown that the prevalence of dyslipidaemia in lupus patients ranges from 36% to 60% at the time of diagnosis, and even higher after three years. 8,17 The present study showed that a total of 21 patients (51.2%) had renal disorders. SLE patients can experience skin, kidney, haematological and musculoskeletal involvement.…”

Section: Discussionsupporting

confidence: 49%

“…It has also been found that dyslipidaemia is common in lupus nephritis patients and it is strongly associated with proteinuria due to the increase in lipid synthesis. 6,17 Our recent study found that the average steroid dose of subjects did not exceed 30 mg/day. However, another study found that 74% of patients had a steroid dose of less than 30 mg/day.…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

<p>Correlation Between Steroid Therapy and Lipid Profile in Systemic Lupus Erythematosus Patients</p>

Atik¹,

Hayati²,

Hamijoyo³

2020

OARRR

View full text Add to dashboard Cite

Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with high mortality and morbidity rates, one of the causes of which is cardiovascular events. Dyslipidaemia is known to be one of the main risk factors for cardiovascular disorders and can be induced by steroid therapy, which is commonly administered to SLE patients. This study aimed to determine whether there is a correlation between steroid dose and lipid profile in SLE patients. Methods: The study was a correlative analytic study with a cross-sectional design. Data were obtained from the Hasan Sadikin Lupus Registry (HSLR) and the medical records of patients registered in the Rheumatology Division, Dr Hasan Sadikin Hospital, Bandung, from 2008 to 2019. Inclusion criteria were SLE patients who had undergone lipid profile examination and received steroid therapy. We excluded patients taking cyclosporine A or statins, and patients treated with steroids for less than a year. A simple random sampling method was performed and Pearson's correlation test was used for the analysis. Results: We recruited 41 female patients with an average age of 30.88 ± 9.29 years old. The average dose of steroid in this study was 5.63 mg/day, while the average lipid profile was 177.51 mg/dL, 105.22 mg/dL, 61 mg/dL and 92.98 mg/dL for total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL) and triglycerides, respectively. Correlations between steroid dose and total cholesterol (r = 0.375; p = 0.016), and between steroid dose and triglyceride level (r = 0.416; p = 0.007) were statistically significant in SLE patients. However, this study showed no correlation between steroid and HDL level (r = 0.206; p = 0.196) or LDL level (r = 0.308; p = 0.05). Conclusion: This study showed that the applied steroid dose in SLE patients correlated with total cholesterol and triglyceride levels, but not with HDL or LDL.

show abstract

Section: Discussionsupporting

confidence: 49%

Section: Discussionmentioning

confidence: 95%

<p>Correlation Between Steroid Therapy and Lipid Profile in Systemic Lupus Erythematosus Patients</p>

Atik¹,

Hayati²,

Hamijoyo³

2020

OARRR

View full text Add to dashboard Cite

show abstract

“…Sajjad et al., have found that 55.4% of lupus nephritis patients had high levels of low-density lipoprotein (LDL). 12…”

Section: Discussionmentioning

confidence: 99%

Characteristics of lupus nephritis in Saudi lupus patients: A retrospective observational study

Albirdisi

Al-Homood

2020

Lupus

View full text Add to dashboard Cite

Objectives Systemic lupus erythematosus (SLE) is a chronic autoimmune multi-systemic disorder of the connective tissue, characterized mainly by involvement of the skin, joints, kidneys, and serosal membranes. It affects females particularly at childbearing age more commonly than males. Lupus nephritis affects around half of patients with SLE. Data about SLE and lupus nephritis in Saudi Arabia are still scarce. In this study, we aimed to evaluate the prevalence, clinical and laboratory findings of SLE and different histological types of lupus nephritis among Saudi patients at King Fahad Medical City. Methods This is a retrospective study for adult patients who have been evaluated at king Fahad medical city between 2014 and 2019 and fulfilled the Systemic Lupus International Collaborating Clinics classification criteria (SLICC). Results 112 patients, 103 (92%) females and 9 (8%) males, with confirmed diagnoses of SLE were reviewed. Skin rash (69.6%), photosensitivity (61.6%), mucosal ulcerations (45.9%), arthralgia and/or arthritis (44.6%) are the most common clinical features. Ninety seven (86.6%) out of 112 patients had a recorded first visit 24 hour urine protein level, out of those only 26 (23.2) patients presented with significant proteinuria of more than 0.5grams per day. Forty four (39.2%) have undergone kidney biopsy. Class IV and III lupus nephritis are the most common reported biopsy results (43.18% and 27.28% respectively). During the study period, three patients (2.7%) developed end-stage kidney disease requiring dialysis and five (4.5%) had renal transplant. Conclusion Our study provided insight on the demographics, characteristics and presentation of SLE patients and the outcome of lupus nephritis in Saudi Arabia.

show abstract

“…LN patients have higher risks for ischemic heart diseases [38,39], which is likely caused by abnormalities in lipid metabolism. It is estimated that 30-50% of LN patients have high plasma total cholesterol and LDL levels [40][41][42]. It is unclear whether elevated miR-148a would contribute to hypercholesterolemia in LN patients by affecting LDL metabolism via the (P)RR.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-148a regulates low-density lipoprotein metabolism by repressing the (pro)renin receptor

Wang

Lin

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

High plasma LDL cholesterol (LDL-c) concentration is a major risk factor for atherosclerosis. Hepatic LDL receptor (LDLR) regulates LDL metabolism, and thereby plasma LDL-c concentration. Recently, we have identified the (pro)renin receptor [(P)RR] as a novel regulator of LDL metabolism, which regulates LDLR degradation and hence its protein abundance and activity. In silico analysis suggests that the (P)RR is a target of miR-148a. In this study we determined whether miR-148a could regulate LDL metabolism by regulating (P)RR expression in HepG2 and Huh7 cells. We found that miR-148a suppressed (P)RR expression by binding to the 3'-untranslated regions (3'-UTR) of the (P)RR mRNA. Mutating the binding sites for miR-148a in the 3'-UTR of (P)RR mRNA completely abolished the inhibitory effects of miR-148a on (P)RR expression. In line with our recent findings, reduced (P)RR expression resulted in decreased cellular LDL uptake, likely as a consequence of decreased LDLR protein abundance. Overexpressing the (P)RR prevented miR-148a-induced reduction in LDLR abundance and cellular LDL uptake. Our study supports a new concept that miR-148a is a regulator of (P)RR expression. By reducing (P)RR abundance, miR-148a decreases LDLR protein abundance and consequently cellular LDL uptake.

show abstract

Frequency of Dyslipidemia in patients with Lupus Nephritis

Cited by 11 publications

References 12 publications

<p>Correlation Between Steroid Therapy and Lipid Profile in Systemic Lupus Erythematosus Patients</p>

<p>Correlation Between Steroid Therapy and Lipid Profile in Systemic Lupus Erythematosus Patients</p>

Characteristics of lupus nephritis in Saudi lupus patients: A retrospective observational study

MicroRNA-148a regulates low-density lipoprotein metabolism by repressing the (pro)renin receptor

Contact Info

Product

Resources

About